Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Elena Shagisultanova, MD, PhD
University of Colorado, Denver
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Arizona
Tucson, Arizona, United States
- University of Colorado Denver
Aurora, Colorado, United States
- Northwestern University
Chicago, Illinois, United States
- New Mexico Cancer Care Alliance
Albuquerque, New Mexico, United States
- Stony Brook University
Stony Brook, New York, United States
- University of Texas Health Science Center San Antonio
San Antonio, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 27 Nov 2017
- Primary completion
- 17 Jan 2023
- Completion
- 7 Feb 2023
- Last update posted
- 13 Nov 2023
- Registered enrollment
- 42
- Registry id
- NCT03054363
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.